We observed a different distribution among the three different groups of treatment (no adjuvant systemic therapy, adjuvant systemic therapy with trastuzumab and without trastuzumab) of the following characteristics that may have conditioned the treatment choice: age, menopausal status, histology, tumor size, grading, Ki67 and hormone receptor status. The gene discussed is NR4A1; the disease is neoplasm.